From: Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies
Development stage
Royalty rate
Pre-clinical
0–5 %
Phase I
5–10 %
Phase II
8–15 %
Phase III
10–20 %
Launched product
20 % +